165 related articles for article (PubMed ID: 27617940)
21. A detailed regimen of isotretinoin for the successful treatment of severe keratosis pilaris.
Kirchner A; Hoyer S
Clin Exp Dermatol; 2022 Mar; 47(3):619-621. PubMed ID: 34780085
[TBL] [Abstract][Full Text] [Related]
22. Multiple squamous cell carcinomas following introduction of nilotinib.
Peters P; Rabbolini D; Sinnya S; Khosrotehrani K; Wagner G
Clin Exp Dermatol; 2014 Oct; 39(7):791-4. PubMed ID: 25155911
[TBL] [Abstract][Full Text] [Related]
23. Āyuṛveda management of keratosis pilaris - a case report.
Vipinsha RS; Prathibha CKB; Anandaraman PVS
J Complement Integr Med; 2020 Jul; 18(1):223-230. PubMed ID: 32692702
[TBL] [Abstract][Full Text] [Related]
24. Keratosis Pilaris.
Pediatr Dermatol; 2019 Nov; 36(6):937-938. PubMed ID: 31778553
[No Abstract] [Full Text] [Related]
25. A case of scurvy associated with nilotinib.
Oak AS; Jaleel T; Fening K; Pavlidakey PG; Sami N
J Cutan Pathol; 2016 Aug; 43(8):725-6. PubMed ID: 27124705
[No Abstract] [Full Text] [Related]
26. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
[TBL] [Abstract][Full Text] [Related]
27. Light and Laser Treatments for Keratosis Pilaris: A Systematic Review.
Kechichian E; Jabbour S; El Hachem L; Tomb R; Helou J
Dermatol Surg; 2020 Nov; 46(11):1397-1402. PubMed ID: 32804891
[TBL] [Abstract][Full Text] [Related]
28. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
29. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
30. Familial erythromelanosis follicularis faciei et colli with extensive keratosis pilaris.
Lalit G; Anubhav G; Kumar KA; Asit M
Int J Dermatol; 2011 Nov; 50(11):1400-1401. PubMed ID: 22004497
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous toxicities of RAF inhibitors.
Anforth R; Fernandez-Peñas P; Long GV
Lancet Oncol; 2013 Jan; 14(1):e11-8. PubMed ID: 23276366
[TBL] [Abstract][Full Text] [Related]
33. Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning.
Tawil MH; El Khoury R; Tomb R; Ghosn M
Int J Trichology; 2017; 9(2):87-89. PubMed ID: 28839396
[TBL] [Abstract][Full Text] [Related]
34. Spiky/keratosis-pilaris-like early follicular mycosis fungoides: A clinicopathologic study of 20 cases with extended follow-up.
Tomasini C; Michelerio A; Quaglino P
J Cutan Pathol; 2021 Sep; 48(9):1124-1132. PubMed ID: 33675561
[TBL] [Abstract][Full Text] [Related]
35. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Cancer Treat Rev; 2012 May; 38(3):241-8. PubMed ID: 21840128
[TBL] [Abstract][Full Text] [Related]
36. [Atrophic red keratosis pilaris of the face in sclerodermiform areas with banal keratosis pilaris; hereditary case].
COSTE F; PIGUET B
Bull Soc Fr Dermatol Syphiligr; 1948; 55(2):135. PubMed ID: 18892029
[No Abstract] [Full Text] [Related]
37. A case for diagnosis (congenital hypotrichosis and keratosis pilaris?).
BLOOM D
Arch Derm Syphilol; 1947 Aug; 56(2):278. PubMed ID: 20257251
[No Abstract] [Full Text] [Related]
38. Papular, profuse, and precocious keratosis pilaris.
Castela E; Chiaverini C; Boralevi F; Hugues R; Lacour JP
Pediatr Dermatol; 2012; 29(3):285-8. PubMed ID: 22141376
[TBL] [Abstract][Full Text] [Related]
39. Pitfalls and pearls in the diagnosis of monilethrix.
Leitner C; Cheung S; de Berker D
Pediatr Dermatol; 2013; 30(5):633-5. PubMed ID: 23834295
[TBL] [Abstract][Full Text] [Related]
40. Nilotinib-induced keratosis pilaris associated with cicatricial alopecia resembling frontal fibrosing alopecia.
Frioui R; Rabhi F; Gargouri F; Jaber K; Dhaoui A
Dermatol Ther; 2021 Jan; 34(1):e14579. PubMed ID: 33236495
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
